What withdrawal symptoms may occur when stopping prednisone and what is the recommended tapering schedule?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Prednisone Withdrawal Symptoms and Tapering

When discontinuing prednisone after long-term use (>3-4 weeks), expect withdrawal symptoms in up to 50% of patients including myalgias, weakness, fatigue, sleep disturbances, and mood changes—these overlap significantly with adrenal insufficiency symptoms but occur even at supraphysiologic doses. 1

Understanding Withdrawal Symptoms

Glucocorticoid withdrawal syndrome develops due to abrupt decreases in glucocorticoid exposure, triggering increased inflammatory cytokines. The key symptoms include:

  • Myalgias and arthralgias (60% of patients)
  • Fatigue and weakness (60%)
  • Sleep disturbances
  • Mood changes
  • Muscular weakness (20%)
  • Loss of appetite (20%)
  • Hypotension (15%)
  • Headaches (5%)

1, 2

Critical Distinction: Withdrawal vs. Adrenal Insufficiency

The total daily prednisone dose determines whether symptoms represent withdrawal syndrome or true adrenal insufficiency:

  • Above 4-6 mg/day prednisone: Symptoms are withdrawal syndrome (not adrenal insufficiency, as the dose remains supraphysiologic)
  • Below 4-6 mg/day prednisone: Symptoms may represent true adrenal insufficiency requiring testing

For example, a patient on 20-40 mg prednisone experiencing symptoms during taper has withdrawal syndrome; adrenal insufficiency concerns only arise when tapering reaches 5-7.5 mg. 1

Recommended Tapering Schedule

Short-Term Therapy (<3-4 weeks)

Stop abruptly without tapering, regardless of dose—no HPA axis suppression expected. 1

Long-Term Therapy (>3-4 weeks)

Use a two-phase taper approach: 1

Phase 1 - Supraphysiologic Range (above 4-6 mg prednisone/day):

  • Taper more rapidly
  • Reduce by 5-10 mg every 1-2 weeks
  • Monitor for withdrawal symptoms but not adrenal insufficiency

Phase 2 - Physiologic Range (approaching 4-6 mg prednisone/day):

  • Slow the taper significantly
  • Reduce by 1-2.5 mg every 2-4 weeks
  • Monitor for both withdrawal symptoms AND adrenal insufficiency

1, 3

Managing Severe Withdrawal Symptoms

If withdrawal symptoms become severe during taper: 1

  1. Temporarily increase the prednisone dose back to the most recent tolerated dose
  2. Extend the duration of the taper (slower reductions)
  3. Resume tapering more gradually once symptoms resolve

Patients with features of exogenous Cushing syndrome require particularly slow tapers, as they experience more severe withdrawal symptoms (typically worsening below 30-35 mg hydrocortisone equivalent or ~7.5 mg prednisone). 1

Testing for Adrenal Recovery

Do not test for adrenal insufficiency while on supraphysiologic doses (>4-6 mg prednisone)—HPA suppression is expected. 1

Once reaching physiologic doses (4-6 mg prednisone), choose one approach: 1

Option 1: Continue gradual taper with clinical monitoring for adrenal insufficiency symptoms

Option 2: Check morning serum cortisol (drawn before taking prednisone):

  • >300 nmol/L (10 μg/dL): Stop prednisone safely
  • 150-300 nmol/L (5-10 μg/dL): Continue physiologic dose, recheck in weeks to months
  • <150 nmol/L (5 μg/dL): Continue physiologic dose, recheck in several months

1

Special Considerations

Switch long-acting glucocorticoids (dexamethasone, betamethasone) to shorter-acting forms (prednisone, hydrocortisone) before tapering. 1

Risk factors for more severe withdrawal:

  • Higher baseline doses
  • Longer treatment duration (>2 years increases symptom incidence)
  • Long-acting glucocorticoid formulations
  • Features of exogenous Cushing syndrome

1, 2

Common Pitfalls

Never abruptly stop prednisone after >3-4 weeks of therapy—this maximizes withdrawal symptoms and risks adrenal crisis. 3

Don't confuse withdrawal symptoms with disease relapse—withdrawal occurs even when the underlying condition is controlled. 1, 4

Avoid routine dynamic testing (ACTH stimulation) during taper—morning cortisol suffices for most patients. 1

Remember that adrenal recovery is highly variable—some patients require up to 12 months for full HPA axis recovery after stopping glucocorticoids. 3, 2

References

2
Research

Steroid withdrawal after long-term medication for immunosuppressive therapy in renal transplant patients: adrenal response and clinical implications.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2004

4
Research

On the various forms of corticosteroid withdrawal syndrome.

The American journal of medicine, 1980

Related Questions

In a patient who took prednisone 20 mg daily for only 5–6 days and now has return of pain and new diarrhea after stopping, is corticosteroid withdrawal unlikely to be responsible for these symptoms?
Does taking oral corticosteroids (e.g., prednisone) with food affect their efficacy or the time to peak effect?
How can I switch from prednisone 20 mg twice daily (bid) to a single daily dose of 40 mg?
What is the prednisone dose in mg/kg twice daily (bid) for a patient weighing 43.1 kg receiving 30 mg twice daily?
Is prednisone safe for renal function?
Can elevated thyroid-stimulating hormone (TSH) cause headaches?
Can buspirone cause hand shaking (tremor) as an adverse effect?
What is the recommended dosing regimen and safety monitoring for Tremfya (guselkumab) in an adult with moderate‑to‑severe plaque psoriasis who has failed topical therapy or phototherapy?
For an adult outpatient with iron‑deficiency anemia who is not on dialysis and has no severe cardiac disease, infection, or IV‑iron hypersensitivity, which is preferred for infusion: Injectafer (ferric carboxymaltose) or Venofer (iron sucrose)?
Should I continue Scemblix (asciminib) while taking Bactrim (trimethoprim‑sulfamethoxazole), and what laboratory monitoring is required?
Is glucosamine safe for renal function in healthy adults, and what precautions are needed for patients with chronic kidney disease or other renal impairment?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.